

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report: **September 14, 2011**
(Date of earliest event reported)

OPKO Health, Inc.
(Exact name of registrant as specified in its charter)

Commission File Number: **001-33528**

Delaware
(State or other jurisdiction of incorporation)

75-2402409
(IRS Employer Identification No.)

4400 Biscayne Blvd., Miami, Florida
(Address of principal executive offices)

33137
(Zip Code)

(305) 575-4100
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On September 14, 2011, OPKO Health, Inc. (the “Company”), in accordance with authority granted by the Board of Directors, approved the transfer of the listing of the Company’s Common Stock, par value \$0.01 per share (“Common Stock”) to the New York Stock Exchange (“NYSE”) from the NYSE Amex. On September 14, 2011, the Company provided written notice to the NYSE Amex that it intends to transfer the listing of its Common Stock to the NYSE. The Company has received authorization from NYSE Regulation, Inc. to transfer the listing of its Common Stock from the NYSE Amex to the NYSE. The Company expects the last day of trading of its Common Stock on the NYSE Amex to be on or about September 15, 2011, and expects the Common Stock to begin trading on the NYSE on or about September 16, 2011, under its current symbol “OPK.” Until it begins trading on the NYSE, the Company’s Common Stock will remain trading on the NYSE Amex under the symbol “OPK.”

Item 7.01 Regulation FD Disclosure.

On September 14, 2011, the Company issued a press release announcing the transfer of the listing of the Company’s Common Stock to the NYSE. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of the Company dated September 14, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

Date: September 14, 2011

By: /s/ Steven D. Rubin

Name: Steven D. Rubin

Title: Executive Vice President-Administration

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of the Company dated September 14, 2011



**OPKO HEALTH TO TRANSFER LISTING OF COMMON STOCK
TO THE NEW YORK STOCK EXCHANGE**

MIAMI, FL— September 14, 2011 – OPKO Health, Inc. (NYSE Amex: OPK) (“OPKO,” “OPKO Health” or the “Company”) today announced that it has received authorization to transfer the listing of its Common Stock from the NYSE Amex to the New York Stock Exchange (“NYSE”). The Company’s Common Stock will continue to trade under the ticker symbol “OPK.” The Company’s Common Stock is expected to begin trading on the NYSE on or about September 16, 2011.

Phillip Frost, M.D., the Company’s Chairman and CEO commented, “Unparalleled access to the global investment community and improved liquidity are important benefits of listing on the NYSE. The move reflects our interest in providing our current and future investor base the most efficient market for trading OPKO’s shares. I would like to thank the NYSE Amex team for their support in managing our listing to this point.”

“As having been part of our community of listed companies with its NYSE Amex listing, we are privileged to welcome OPKO Health to the New York Stock Exchange,” said Duncan L. Niederauer, CEO, NYSE Euronext. “We value OPKO Health’s ongoing partnership and reaffirm our commitment to the company and its shareholders to provide the highest levels of market quality, liquidity and service.”

The Company has notified the NYSE Amex that it will voluntarily delist its Common Stock from the NYSE Amex. The last day of trading of the Common Stock on the NYSE Amex is expected to be on or about September 15, 2011. Until the Company’s Common Stock begins trading on the NYSE, the Company’s Common Stock will remain trading on the NYSE Amex under the ticker symbol “OPK.”

About OPKO Health, Inc.

We are a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development and commercialization expertise and our novel and proprietary technologies.

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements regarding the transfer of the listing of the Company’s Common Stock from the NYSE Amex to the NYSE, the improved liquidity for our common stock, and the unparalleled access to global investment community. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include the Company’s ability to continue to comply with the NYSE listing standards and those described in our filings with the Securities and Exchange Commission. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-

looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Contacts:

Steven D. Rubin
305 575-6015